Clinical trials: CtDNA
Ovarian Cancer, Triple-Negative Breast Cancer
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer…
- Conditions
- Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer
- Trial name
- SCANDARE (NCT03017573)
- Testing
- Tumor biopsies / Tumor surgery, Blood withdrawal
- Where
- 6 sites in France
- Volunteers
- 1,050 people
- Sponsor
- Institut Curie
Triple Negative Breast Cancer
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon…
- Trial name
- CUPCAKE (NCT06225505)
- Testing
- ctDNA monitoring, 68Ga-FAPI-46-PET-CT
- Where
- 13 sites in France
- Volunteers
- 450 people
- Sponsor
- Institut Curie
Minimal Residual Disease, Adjuvant Chemotherapy
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this…
- Conditions
- Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib
- Trial name
- NCT07136077
- Testing
- Tislelizumab, Fruquintinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Colorectal Cancer
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT04786600
- Testing
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Cancer, Head and Neck Squamous Cell Carcinoma
Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma
This research study will include patients with high risk locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx and patients that are starting on standard…
- Conditions
- Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT04599309
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Next-Generation-Sequencing
CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01
In cooperation with the molecular tumor board of the University Hospital Tübingen (UKT), a prospective collection of blood samples during the course of therapy is planned.
- Trial name
- CIRCULATING-01 (NCT05871593)
- Testing
- Molecular genetic diagnostic
- Volunteers
- 200 people
- Sponsor
- University Hospital Tuebingen
Oesophageal Cancer
Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab
Patients with cancer are increasingly being treated with drugs designed to modulate the response of their immune system, broadly to boost their body's defences against cancer.
- Trial name
- CALIBRATION (NCT03653052)
- Testing
- Durvalumab
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Simon C Pacey, MD
Prostatic Neoplasms
Analysis of Androgene Receptors Axis and DNA Damage Repair Genes in Patients With Prostate Cancer
In this project, we would like to focus on castration-sensitive prostate cancer (CRPC). This is a highly variable clinical picture with differentiated and burdening symptoms.
- Trial name
- NCT03677414
- Where
- Austria
- Volunteers
- 59 people
- Sponsor
- Medical University of Graz
Liver Metastasis Colon Cancer, ctDNA Genotype
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM).
- Conditions
- Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment
- Trial name
- NCT06199232
- Testing
- HAIC+targeted therapy+PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University
Stomach Neoplasms, Metastasis
Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
To investigate the value of CTCs and ctDNA in the diagnosis of metastasis in ascites/peritoneal flushing fluid and blood; To investigate the influence of laparoscopic CO2 pneumoperitoneum establishment on peritoneal and…
- Trial name
- CTC_ctDNA (NCT05208372)
- Testing
- CTC test, ctDNA test
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- First Hospital of China Medical University
Esophageal Squamous Cell Carcinoma
Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer
The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0~pI esophageal squamous cell carcinoma and pII~pIV esophageal squamous cell carcinoma by…
- Trial name
- NCT03922230
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer
ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
This study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to determine whether ribociclib plus endocrine therapy (ET) is non-inferior to adjuvant chemotherapy followed by ribociclib plus…
- Trial name
- RACE (NCT07423611)
- Testing
- Aromatase inhibitor (± ovarian suppression) plus Ribociclib, 4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
- Where
- China
- Volunteers
- 388 people
- Sponsor
- Fudan University
Malignant Phyllodes Tumor of the Breast
Dynamic ctDNA Monitoring in Advanced Malignant Phyllodes Tumors of the Breast
Malignant phyllodes tumor of the breast is a rare fibroepithelial tumor. Patients with metastatic or unresectable disease have limited systemic treatment options, and there remains a need for biomarkers that can dynamically…
- Trial name
- NCT07903181
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis.
- Trial name
- NCT06992336
- Testing
- Apatinib, Camrelizumab, Capecitabine
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast…
- Trial name
- FITWISE (NCT06518837)
- Testing
- Tirzepatide
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or…
- Trial name
- CLAUDE (NCT05350501)
- Testing
- EO2040
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Enterome
Carcinoma, Non-small-cell Lung Cancer
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations.
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Thoracic Neoplasms
- Trial name
- NCT02833467
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Esophageal Squamous Cell Carcinoma
Individualized Tumor-Informed CtDNA Analysis for Monitoring Postoperative Recurrence in ESCC (NEOCRTEC2401)
The goal of this observational study or is to explore the correlation between dynamic changes in postoperative circulating tumor DNA (ctDNA) and recurrence risk using a novel, tumor-informed ctDNA detection technique, thus laying…
- Trial name
- NCT06561178
- Testing
- molecular residual disease detection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Breast Cancer Stage IV
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
After an initial screening phase (SAFIR 03 - SCREENING) to identify patients with blood circulating mutated-PIK3CA tumours persistent, patients will be enrolled in the treatment phase of SAFIR 03 (SAFIR 03 - ARRIBA) that was…
- Trial name
- SAFIR 03 (NCT05625087)
- Testing
- Alpelisib, Ribociclib
- Where
- 44 sites in France
- Volunteers
- 4 people
- Sponsor
- UNICANCER
Genetic Change
Study on Gene Evolution in Glioma Under Stress Therapy
Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF)…
- Trial name
- NCT05512325
- Testing
- Gene evolution and molecular response under Bevacizumab treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Henan Provincial People's Hospital